Company Overview and News

 
Duke Energy to Provide $38M in Tax Savings to Customers

2018-04-17 zacks
Duke Energy Corp. (DUK - Free Report) will offer a notable $38 million in annual tax savings on electric and natural gas bills for its customers in Ohio and Kentucky, beginning from April and May 2018. The Tax Cuts and Jobs Act that came into effect on Jan 1, 2018, clearly led to this entire bill reduction. Details of Projected Tax Savings In particular, Duke Energy’s customers, residing in Ohio, would save approximately $20 million in annual tax on their electric bills.
Upvote Downvote

 
EQT Midstream to Expand Mountain Valley Pipeline to South

2018-04-16 zacks
EQT Midstream Partners, LP (EQM - Free Report) has recently revealed its intention to build a natural gas pipeline to connect Virginia and North Carolina. The interstate MVP Southgate pipeline project is backed by shipping commitment from SCANA Corporation's (SCG - Free Report) subsidiary PSNC Energy.
Upvote Downvote

 
WGL Holdings-AltaGas Merger Gets Another Regulatory Approval

2018-04-06 zacks
WGL Holdings, Inc (WGL - Free Report) announced the receipt of approval from Maryland Public Service Commission for its merger with AltaGas Ltd. (ALA.TO). The merger is valued at $4.5 billion. Subject to approval from the Public Service Commission of District of Columbia, the merger, which was announced on Jan 25, 2017, is expected to be completed by the first half of 2018. Approval Subject to Conditions Maryland Public Service Commission’s approval for the merger of the complementary energy companies is subject to the fulfillment of certain conditions.
Upvote Downvote

 
WGL / WGL Holdings, Inc. 8-K (Current Report)

2018-03-16 sec.gov
Document UNITED STATES
Upvote Downvote

 
WGL / WGL Holdings, Inc. 424B2 (Prospectus)

2018-03-13 sec.gov
424B2 Table of Contents Filed pursuant to Rule 424(b)(2) Registration No. 333-220479 CALCULATION OF REGISTRATION FEE
Upvote Downvote

 
WGL / WGL Holdings, Inc. FWP

2018-03-12 sec.gov
FWP Filed Pursuant to Rule 433 Registration No. 333-220479 March 12, 2018 WGL HOLDINGS, INC. Pricing Term Sheet <
Upvote Downvote

 
WGL / WGL Holdings, Inc. 424B5 (Prospectus)

2018-03-12 sec.gov
424B5 Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-220479 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securitie
Upvote Downvote

 
AltaGas-WGL... Will The Marriage Happen?

2018-03-08 seekingalpha
AltaGas (OTCPK:ATGFF) and WGL Holdings (WGL) announced a merger in January of 2017. The current expected timeline of closing is mid-year 2018.
Upvote Downvote

1
Should You Continue To Hold On To Altagas And Its 9.2% Yielding Dividend?

2018-03-06 seekingalpha
The company is still waiting for the final regulatory approval to close its acquisition of WGL Holdings.
Upvote Downvote

 
Altagas Hikes: Stock Dives: Why The Market Remains Spooked

2018-03-05 seekingalpha
It is a hostile market for yield. We have no doubt about this. Stocks are seeing prices that were previously thought of as impossible. So when Altagas (OTCPK:ATGFF) joined the ranks of "The Walking Red" we were not too surprised. We did however examine the financials to figure out what made the market finally realize that this needed to go much lower.
Upvote Downvote

 
6 Notable Dividend Stocks Boost Payouts, Including Altria | InvestorPlace

2018-03-05 investorplace
The S&P 500 Index slid last week as the Federal Reserve reaffirmed plans to continue raising interest rates in 2018. Meanwhile, investors fretted over the potential knock-on effects from Trump administration plans for tariffs on steel and aluminum imports. Despite the volatility, a number of dividend stock companies demonstrated confidence in their operations by announcing payout raises.
Upvote Downvote

 
At Least 2, Possibly 3 Double-Digit Payout Increases Expected In March

2018-03-01 seekingalpha
13 dividend growth companies I track announced their annual increases in the latter half of February.
Upvote Downvote

 
Multiple Double-Digit Payout Increases In The First 2 Weeks Of February

2018-02-20 seekingalpha
13 dividend growth companies I track announced their annual increases in the first half of February.
Upvote Downvote

 
WGL / WGL Holdings, Inc. / STATE STREET CORP - WGL HOLDINGS, INC. (Passive Investment)

2018-02-13 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 ANNUAL FILING WGL HOLDINGS, INC. (NAME OF ISSUER) COMMON STOCK (TITLE OF CLASS OF SECURITIES) 92924F106 (CUSIP NUMBER) 12/31/2017 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT) CHECK THE APPROPRIATE BOX TO DESIGNATE THE RULE PURSUANT TO WHICH THIS SCHEDULE IS FILED: (X) RULE 13D-1 (B) ( ) RULE 13D-1 (C) ( ) RULE 13D-1 (D) *THE REMAINDER OF THIS COVER PAGE SHALL
Upvote Downvote

 
WGL / WGL Holdings, Inc. / STATE STREET CORP - WGL HOLDINGS, INC. (Passive Investment)

2018-02-13 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 ANNUAL FILING WGL HOLDINGS, INC. (NAME OF ISSUER) COMMON STOCK (TITLE OF CLASS OF SECURITIES) 92924F106 (CUSIP NUMBER) 12/31/2017 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT) CHECK THE APPROPRIATE BOX TO DESIGNATE THE RULE PURSUANT TO WHICH THIS SCHEDULE IS FILED: (X) RULE 13D-1 (B) ( ) RULE 13D-1 (C) ( ) RULE 13D-1 (D) *THE REMAINDER OF THIS COVER PAGE SHALL
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 92924F106